TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07677514: A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease

Sponsor: Jiangsu Carephar Pharmaceutical Co., Ltd. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 156 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,656,500

Rescue Site Savings

+$1,759,500

Unlock Full NCT07677514 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07677514 Rescue Dossier →